Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Integrated BioPharma Inc. (INBP) had Revenue of $13.95M for the most recently reported fiscal quarter, ending 2025-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-03-31

Income Statement Financials
Revenue	$13.95M
Net Income	$0.61M
Cost of Goods Sold	$12.40M
Gross Profit	$1.55M
Operating Expenses	$13.21M
Operating Income	$0.74M
Non-Operating Income/Expense	$0.04M
Pre-Tax Income	$0.78M
Normalized Pre-Tax Income	$0.78M
Income after Taxes	$0.61M
Income from Continuous Operations	$0.61M
Consolidated Net Income/Loss	$0.61M
Normalized Income after Taxes	$0.61M
EBIT	$0.74M
EBITDA	$1.04M
Weighted-Average Shares Outstanding (Basic)	30.30M
Weighted-Average Shares Outstanding (Diluted)	31.52M
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.02
Balance Sheet Financials
Current Assets	$18.55M
Property, Plant, and Equipment	$1.81M
Long-Term Assets	$7.11M
Total Assets	$25.66M
Current Liabilities	$4.98M
Long-Term Debt	$0.03M
Long-Term Liabilities	$0.29M
Total Liabilities	$5.27M
Common Equity	$20.38M
Tangible Shareholders Equity	$20.38M
Shareholders Equity	$20.38M
Common Shares Outstanding	30.30M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$1.47M
Cash Flow from Investing Activities	$-0.20M
Cash Flow from Financial Activities	$0.01M
Beginning Cash	$1.68M
End Cash	$2.96M
Increase/Decrease in Cash	$1.28M
Stock-Based Compensation	$0.14M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.72
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.00
Debt to Equity Ratio	0.00
Gross Margin	11.12%
Operating Margin	5.30%
EBIT Margin	5.30%
EBITDA Margin	--
Pre-Tax Profit Margin	5.58%
Profit Margin	4.38%
Free Cash Flow	$1.27M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.54
Inventory Turnover	1.23
Receiveable Turnover	2.75
Days Sales in Receivables	32.78
Return on Equity	3.00%
Return on Tangible Equity	3.00%
Return on Assets	2.38%
Return on Investments	2.99%
Book Value Per Share	$0.67
Free Cash Flow per Share	$0.04
Operating Cash Flow per Share	$0.05

Data from Zacks Investment Research, Inc.